The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Does the presence of CHIP impact overall survival in patients with multiple myeloma?
In this video, Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, provides insight into a study investigating the impact of clonal hematopoiesis of indeterminate potential (CHIP) on overall survival (OS) in patients with multiple myeloma (MM). Dr Raje notes that while CHIP is not uncommon, particularly in older adults, it does not appear to impact survival outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
